Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains

dc.contributor.authorCarcas, Antonio J.
dc.contributor.authorSevillano, David
dc.contributor.authorGonzález, Natalia
dc.contributor.authorAlou, Luis
dc.contributor.authorGómez Gil, Rosa
dc.contributor.authorMuñoz, Mario
dc.contributor.authorLlanos, Lucía
dc.contributor.authorSánchez Villanueva, Rafael J.
dc.contributor.authorGonzález Parra, Emilio
dc.contributor.authorGiménez Mestre, María José
dc.contributor.authorAguilar, Lorenzo
dc.date.accessioned2022-02-17T15:34:01Z
dc.date.available2022-02-17T15:34:01Z
dc.date.issued2019
dc.description.abstractObjectives: Bacterial viability and enrichment of resistance resulting from three different amikacin administration schedules with respect to haemodialysis (HD) were assessed against three OXA-48-producing Klebsiella pneumoniae isolated during an outbreak in a Spanish hospital. Methods: A previously described two-compartment dynamic system was used. Three possible amikacin administration schedules were simulated: (i) haemodialysis immediately after amikacin infusion (pre-HD); (ii) infusion immediately after haemodialysis (post-HD); and (iii) infusion at 50% interdialytic period. Amikacin standard dose (SD) and double dose (DD) were simulated for each schedule. Values of Cmax/MIC, Cmax/MPC (mutant prevention concentration), AUC0-48h/MIC, AUC0-48h/MPC and %TMSW (percentage of time that the concentration was inside the mutant selection window) were determined with experimental data and were correlated with the area under the bacterial killing curve of the total population and the resistant subpopulation. Results: Both with SD and DD, the pre-HD schedule resulted in increases at 48h in bacterial counts of the total population at the expense of enrichment of pre-existing resistant subpopulations from 12h onwards for all strains. The estimated %TMSW that prevented enrichment of resistant mutants was <61.5%. The AUC0-48h/MPC (with values of ≈40 being associated with countering of increases in resistant subpopulations) was better than the %TMSW as a predictive parameter. Conclusion: This study showed that the longest times concentrations were above the MPC (i.e. highest AUC0-48h/MPC, lowest %TMSW), the lowest enrichment of resistant subpopulations. This implies use of the highest possible amikacin dose (limited by toxicity) and post-HD as the best administration schedule.spa
dc.description.filiationUEMspa
dc.description.impact2.706 JCR (2019) Q2, 133/271 Pharmacology & Pharmacyspa
dc.description.impact0.762 SJR (2019) Q3, 57/129 Microbiology (medical)spa
dc.description.impactNo data IDR 2019spa
dc.description.sponsorshipSin financiaciónspa
dc.identifier.citationCarcas, A. J., Sevillano, D., González, N., Alou, L., Gómez-Gil, R., Muñoz, M., Llanos, L., Sánchez-Villanueva, R. J., González-Parra, E., Giménez, M. J., & Aguilar, L. (2019). Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains. Journal of Global Antimicrobial Resistance, 19, 241-251. https://doi.org/10.1016/j.jgar.2019.05.027spa
dc.identifier.doi10.1016/j.jgar.2019.05.027
dc.identifier.issn2213-7165
dc.identifier.issn2213-7173
dc.identifier.urihttp://hdl.handle.net/11268/10764
dc.language.isoengspa
dc.peerreviewedSispa
dc.rights.accessRightsrestricted accessspa
dc.subject.otherAmicacinaspa
dc.subject.otherDiálisis renalspa
dc.subject.unescoFarmacologíaspa
dc.subject.unescoMedicamentospa
dc.subject.unescoEfectos fisiológicosspa
dc.titleEvaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strainsspa
dc.typejournal articlespa
dspace.entity.typePublication
relation.isAuthorOfPublication30f94dc4-9c8a-4ec2-b3f9-c3d404ce9bfa
relation.isAuthorOfPublication.latestForDiscovery30f94dc4-9c8a-4ec2-b3f9-c3d404ce9bfa

Files